Table 7.
Comparison of the occurrence of adverse reactions between groups
| Variable | Gastrointestinal symptoms | Rash | Muscular symptoms | ALT ≥3 × ULN | Upper respiratory tract symptoms | Total incidence n (%) |
|---|---|---|---|---|---|---|
| Control group (n=55) | 6 | 2 | 4 | 2 | 1 | 15 (9.5) |
| PCSK9 inhibitor group (n=55) | 1 | 2 | 0 | 1 | 1 | 5 (8.9) |
| χ2 | 0.529 | 1.198 | 1.445 | 0.081 | 0.593 | 0.016 |
| P | 0.467 | 0.274 | 0.229 | 0.776 | 0.441 | 0.899 |
Note: All data are presented as n (%). Abbreviations: ALT, alanine aminotransferase; PCSK9, proprotein convertase subtilisin/kexin 9; ULN, upper limit of normal.